Ischemic preconditioning in the intact rat heart is mediated by but not μ- or κ-opioid receptors

Circulation

Volumn 97, Issue 13, 1998, Pages 1282-1289

  Schultz, Jo El J ^a   Hsu, Anna K ^a   Gross, Garrett J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Herat diseases; Ischemia; Myocardial infarction; Receptors; Signal transduction

Indexed keywords

ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; SIGMA 1 OPIATE RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CONDITIONING; DRUG RECEPTOR BINDING; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

EID: 0343041621     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.13.1282     Document Type: Article

References (43)

1. Lord JAH, Waterfield AA, Hughes J, Kosterlitz HW. Endogenous opioid peptides: multiple agonists and receptors. Nature. 1977:267:495-500.
2. Miller RJ. Multiple opiate receptors for multiple opioid peptides. Med Biol. 1982;60:1-6.
3. Paterson SJ, Robson LE, Kosterlitz HW. Classification of opíoíd receptors. Br Med Bull. 1983;39:1-36.
4. Goldstein A, James IF. Multiple opioid receptors: criteria for identification and classification. Trends Pharmacol Sci. 1984;5:503-505.
5. Dhawan BN, Cesselin F, Raghubir R, Reisine T, Bradley PB, Portoghese PS, Hamon M. International union of pharmacology XII: classification of opioid receptors. Pharmacol Rev. 1996;48:567-592.
6. 6]enkephalin and naltrindole 5-isothiocyanate: evidence for delta receptor subtypes. J Pharmacol Exp Ther. 1991;257:1069-1075.
7. 2]deltorphin II in mice: evidence for delta receptor subtypes. J Pharmacol Exp Ther. 1991;258:583-587.
8. Sofuoglu M, Portoghese PS, Takemori AE. Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: evidence for delta opioid receptor subtypes. J Pharmacol Exp Ther. 1991;257:676-680.
9. Arrigo-Reina R, Ferri S. Evidence for an involvement of the opioid peptidergic system in the reaction to stressful condition. Eur J Pharmacol. 1980;64:85-88.
10. Ferri S, Arrigo-Reina R, Candeletti S, Costa S, Murari G, Speroni E, Scoto G. Central and peripheral sites of action for the protective effect of opioids on the rat stomach. Pharmacol Res Commun. 1983;15:409-418.
11. Ferri S, Speroni E, Candeletti S, Cavicchini E, Romualdi P, Govoni P, Marchini M. Protection by opioids against gastric lesions caused by necrotizing agents. Pharmacology. 1988;36:140-144.
12. Mayfield KP, D'Alecy LG. Role of endogenous opioid peptides in the acute adaptation to hypoxia. Brain Res. 1992;582:226-231.
13. 5]-enkephalin). J Thorac Cardiovasc Surg. 1994;107:964-967.
14. Mayfield KP, D'Alecy LG. Delta-1 opioid agonist acutely increases hypoxic tolerance. J Pharmacol Exp Ther. 1994;268:683-688.
15. Mayfield KP, D'Alecy LG. Delta-1 opioid receptor dependence of acute hypoxic adaptation. J Pharmacol Exp Ther. 1994;268:74-77.
16. Schultz JJ, Rose E, Yao Z, Gross GJ. Evidence for involvement of opioid receptors in ischemic preconditioning in rat hearts. Am J Physiol. 1995;268:H2157-H2161.
17. Schultz JJ, Hsu AK, Gross GJ. Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart. Circ Res. 1996;78:1100-1104.
18. Schultz JJ, Hsu AK, Gross GJ. Ischemic preconditioning and morphineinduced cardioprotection involve the delta (δ)-opioid receptor in the intact rat heart. J Mol Cell Cardiol. 1997;29:2187-2195.
19. Chien GL, Van Winkle DM. Naloxone blockade of myocardial ischemic preconditioning is stereoselective. J Mol Cell Cardiol. 1996;28:1895-1900.
20. Miki T, Downey J. Opioid receptors participate in ischemic preconditioning in rabbits. J Mol Cell Cardiol. 1996;28:A187. Abstract.
21. Holaday JW. Cardiovascular effects of endogenous opiate systems. Ann Rev Pharmacol Toxicol. 1983;23:541-594.
22. Martin WR. Pharmacology of opioids. Pharmacol Rev. 1983;35:283-323.
23. Wong TM, Lee AYS, Tai KK. Effects of drugs interacting with opioid receptors during normal perfusion or ischemia and reperfusion in the isolated rat heart: an attempt to identify cardiac opioid receptor subtype(s) involved in arrhythmogenesis. J Mol Cell Cardiol. 1990;22:1167-1175.
24. Siren A-L, Feuerstein G. The opioid system in circulatory control. News Physiol Sci. 1992;7:26-30.
25. Klein HH, Puschmann S, Schaper J, Schaper W. The mechanism of the tetrazolium reaction in identifying myocardial infarction. Virchows Arch. 1981;393:287-297.
26. 1-opioid receptor antagonist: 7-benzylidenenaltrexone. Eur J Pharmacol. 1992;218:195-196.
27. Takemori AE, Sultana M, Nagase H, Portoghese PS. Agonist and antagonist activities of ligands derived from naltrexone and oxymorphone. Life Sci. 1992;50:1491-1495.
28. Sofuoglu M, Portoghese PS, Takemori AE. 7-benzylidenenaltrexone (BNTX): a selective δ1 opioid receptor antagonist in the mouse spinal cord. Life Sci. 1993;52:769-775.
29. Takemori AE, Larson DL, Portoghese PS. The irreversible narcotic antagonistic and reversible agonistic properties of the fumarate methyl ester derivative of naltrexone. Eur J Pharmacol. 1981;70:445-451.
30. Ward SJ, Portoghese PS, Takemori AE. Pharmacological characterization in vivo of the novel opiate, β-Funaltrexamine. J Pharmacol Exp Ther. 1982;220:494-498.
31. Portoghese PS, Lipkowski AW, Takemori AE. Bimorphinans as highly selective, potent κ opioid receptor antagonists. J Med Chem. 1987;30:238-239.
32. Portoghese PS, Lipkowski AW, Takemori AE. Binaltorphimine and norBinaltorphimine, potent and selective κ-opioid receptor antagonists. Life Sci. 1987;40:1287-1292.
33. Ela C, Barg J, Vogel Z, Hasin Y, Eilam Y. Distinct components of morphine effects on cardiac myocytes are mediated by the κ and δ opioid receptors. J Mol Cell Cardiol. 1997;29:711-720.
34. Jiang Q, Mosberg HI, Porreca F. Modulation of the potency and efficacy of mu-mediated antinociception by delta agonists in the mouse. J Phamacol Exp Ther. 1990;254:683-689.
35. 125I]β-endorphin to opioid receptors in rat striatal membranes: biochemical evidence for the existence of a mu/delta opioid receptor complex, J Pharmacol Exp Ther. 1990;253:419-426.
36. 5]-enkephalin and dynorphin A-(1-17) of the inhibitory bladder motility effects of selected mu agonists in vivo. J Phurmacal Exp Ther. 1989;249:462-469.
37. Traynor JR, Elliott J. δ-Opioid receptor subtypes and cross-talk with μ-receptors. Trends Phamacol Sci. 1993;14:84-86.
38. Krumins SA, Faden AI, Feuerstein G. Opiate binding in rat hearts: modulation of binding after hemorrhagic shock. Biochem Biophys Res Commun. 1985;127:120-128.
39. Ventura C, Bastagli L, Bernardi P, Caldarera CM, Guarnieri C. Opioid receptors in rat cardiac sarcolemma: effect of phenylephrine and isoproterenol. Biochim Biophys Acta. 1989;987:69-74.
40. 2+ release from an intracellular pool in myocytes and neurons. Circ Res. 1992;70:66-81.
41. Zimlichman R, Gefel D, Eliahou H, Matas Z, Rosen B, Gass S, Ela C, Eilam Y, Vogel Z, Barg J. Expression of opioid receptors during heart ontogeny in normotensive and hypertensive rats. Circulation. 1996;93:1020-1025.
42. Xia Q, Zhang W-M, Shen Y-L, Wong TM. Decreased affinity of κ-receptor binding during reperfusion following ischaemic preconditioning in the rat heart. Life Sci. 1996;58:1307-1313.
43. Niroomand F, Mura RA, Piacentini L, Kubler W. Opioid receptor agonists activate pertussis toxin-sensitive G proteins and inhibit adenylyl cyclase in canine cardiac sarcolemma. Naunyn Schmiedebergs Arch Pharmacal. 1996;354:643-649.